Fluorodeoxyglucose PET/CT in subcutaneous sarcoidosis mimicking cutaneous lymphoma

Diffuse Cutaneous Angiosarcoma in the Scalp and Face Demonstrated on FDG PET/CT Imaging

ABSTRACT

Diffuse cutaneous angiosarcomas are rare. Herein, we reported FDG PET/CT findings of cutaneous angiosarcoma in a 59-year-old man. FDG PET/CT imaging was performed for staging, showing diffuse intense FDG uptake with an SUVmax of 19 in the scalp and face. Chemotherapy was recommended for this patient because surgery and radiotherapy were not appropriate due to the widespread skin involvement. Our case suggests that cutaneous angiosarcoma can present with diffuse skin involvement, and FDG PET/CT plays an important role in determining the treatment plan to avoid unnecessary surgery and radiotherapy.

The utility of positron emission tomography with and without computed tomography in patients with nonmelanoma skin cancer

Combined positron emission tomography (PET) and computed tomography (CT) scans are widely used in the staging and monitoring of most malignancies. The differential for PET-positive cutaneous lesions includes primary skin cancers, infections, cutaneous metastases from distant malignancies, and benign neoplasms. In dermatology, PET/CT scans have been most widely studied in patients with melanoma and Merkel cell carcinoma. The role of PET/CT scans in the management of other cutaneous malignancies is less clear, but it has shown great promise in the management of patients with squamous cell carcinoma and cutaneous lymphoma. This review seeks to address the usefulness of PET/CT scans in nonmelanoma skin cancer and to provide guidance regarding the management of patients with incidental PET-positive nodules. Currently, there is limited experience with PET/CT scans for staging and monitoring of non-head and neck metastatic basal cell and squamous cell carcinomas, and results show limited sensitivity and specificity. We also address the evidence for management of an incidental PET-positive cutaneous nodule and recommend obtaining a biopsy specimen in patients with a known noncutaneous malignancy, a history of primary skin cancer, or a high risk of either cutaneous or noncutaneous malignancy.